Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences: ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of its underwritten offering of $475.0 million aggregate principal amount of 0.50% convertible senior notes due 2032 (the "Notes") ...

(TVTX) on Monday reported a loss of $37.1 million in its first quarter.

Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year over ...

For the quarter ended March 2026, Travere Therapeutics (TVTX) reported revenue of $127.2 million, up 55.6% over the same period last year. EPS came in at -$0.39, compared to -$0.47 in the year-ago ...

Travere Therapeutics Inc. (NASDAQ:TVTX) reported first quarter results that fell short of Wall Street expectations, with both earnings and revenue missing analyst ...

Travere Therapeutics TVTX posted a profit for the first quarter on Monday. The company reported quarterly earnings of 5 cents ...

LightPath Technologies, Inc. ("LightPath," the "Company," "we," or "our"), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today ...

SenesTech, Inc. , the leader in fertility control for managing animal pest populations and the only manufacturer of EPA-compliant Rodent Birth Controltm products, will report financial results for its ...

Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE)-- Ligand Pharmaceuticals ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.